Evidence map›Paper›PMID 35322769›Full record

ArticleEuropean psychiatry : the journal of the Association of European Psychiatrists2022

Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.

Christoph U Correll, Michael Tocco, Jay Hsu, Robert Goldman, Andrei Pikalov

Open access · goldAbstract read
In one paragraph

Article in European psychiatry : the journal of the Association of European Psychiatrists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Christoph U CorrellDepartment of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY, USA.ORCID https://orcid.org/0000-0002-7254-5646
Michael ToccoSunovion Pharmaceuticals Inc, Fort Lee, NJ, and Marlborough, MA.ORCID https://orcid.org/0000-0003-1474-6666
Jay HsuSunovion Pharmaceuticals Inc, Fort Lee, NJ, and Marlborough, MA.ORCID https://orcid.org/0000-0002-1210-171X
Robert GoldmanSunovion Pharmaceuticals Inc, Fort Lee, NJ, and Marlborough, MA.
Andrei PikalovSunovion Pharmaceuticals Inc, Fort Lee, NJ, and Marlborough, MA.ORCID https://orcid.org/0000-0003-4206-9519
Sunovion (United States) · USNorthwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atypical antipsychoticcontrolled clinical triallurasidoneschizophreniasecond generation antipsychotic

Identifiers

PMID35322769
PMCPMC9058440
OpenAlexW4220953809

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.